Skip to content
akaturk Academic measurement
Search

OpenAlex topic

Rheumatoid Arthritis Research and Therapies

This page lists works and academicians tagged with an OpenAlex topic. It is not a YÖKSİS primary or secondary field.

OpenAlex 6,338 works 270 author topics

Works

6,338 works

  1. YÖKSİS JCR Q1 OpenAlex top 1% OpenAlex 100.0%

    OBJECTIVE: The Systemic Lupus International Collaborating Clinics (SLICC) group revised and validated the American College of Rheumatology (ACR) systemic lupus erythematosus (SLE) classification criteria in order to improve clinical relevance, meet stringent methodology requirements, and incorporate new knowledge rega…

  2. OpenAlex top 1% OpenAlex 100.0%

    BACKGROUND: The burden of inflammatory bowel disease (IBD) is rising globally, with substantial variation in levels and trends of disease in different countries and regions. Understanding these geographical differences is crucial for formulating effective strategies for preventing and treating IBD. We report the preva…

  3. YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 100.0%

    BACKGROUND: Increases in lipid levels and cancers with tofacitinib prompted a trial of major adverse cardiovascular events (MACE) and cancers in patients with rheumatoid arthritis receiving tofacitinib as compared with a tumor necrosis factor (TNF) inhibitor. METHODS: We conducted a randomized, open-label, noninferior…

  4. YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 100.0%

    BACKGROUND: Increases in lipid levels and cancers with tofacitinib prompted a trial of major adverse cardiovascular events (MACE) and cancers in patients with rheumatoid arthritis receiving tofacitinib as compared with a tumor necrosis factor (TNF) inhibitor. METHODS: We conducted a randomized, open-label, noninferior…

  5. YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 100.0%

    BACKGROUND: Increases in lipid levels and cancers with tofacitinib prompted a trial of major adverse cardiovascular events (MACE) and cancers in patients with rheumatoid arthritis receiving tofacitinib as compared with a tumor necrosis factor (TNF) inhibitor. METHODS: We conducted a randomized, open-label, noninferior…

  6. YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 100.0%

    BACKGROUND: Increases in lipid levels and cancers with tofacitinib prompted a trial of major adverse cardiovascular events (MACE) and cancers in patients with rheumatoid arthritis receiving tofacitinib as compared with a tumor necrosis factor (TNF) inhibitor. METHODS: We conducted a randomized, open-label, noninferior…

  7. OpenAlex top 1% OpenAlex 100.0%

    No abstract yet.

  8. YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 100.0%

    No abstract yet.

  9. YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.9%

    No abstract yet.

  10. YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 100.0%

    BACKGROUND: Secukinumab is an anti-interleukin-17A monoclonal antibody that has been shown to control the symptoms of ankylosing spondylitis in a phase 2 trial. We conducted two phase 3 trials of secukinumab in patients with active ankylosing spondylitis. METHODS: In two double-blind trials, we randomly assigned patie…

  11. YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 100.0%

    BACKGROUND: Secukinumab is an anti-interleukin-17A monoclonal antibody that has been shown to control the symptoms of ankylosing spondylitis in a phase 2 trial. We conducted two phase 3 trials of secukinumab in patients with active ankylosing spondylitis. METHODS: In two double-blind trials, we randomly assigned patie…

  12. YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 100.0%

    No abstract yet.

Academicians

270 academicians